Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl≥50 mL/min: A Retrospective Cohort Study
Conclusion: For NVAF patients with CrCl≥50 mL/min in China, low-dose rivaroxaban (10 mg/day) is a viable alternative to standard doses in preventing IS/SE. In nonoverweight patients (BMI<24 kg/m2), it offers comparable efficacy with enhanced safety.
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/cdr/7021330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Conclusion: For NVAF patients with CrCl≥50 mL/min in China, low-dose rivaroxaban (10 mg/day) is a viable alternative to standard doses in preventing IS/SE. In nonoverweight patients (BMI<24 kg/m2), it offers comparable efficacy with enhanced safety. |
|---|---|
| ISSN: | 1755-5922 |